CIDP associated with Sjögren's syndrome.
CIDP
Neuro-sjögren
Sjögren
Sjögren’s syndrome
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
10
01
2021
accepted:
09
02
2021
revised:
09
02
2021
pubmed:
22
2
2021
medline:
22
7
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
This study addresses the challenging characterisation and differentiation of CIDP versus CIDP in association with Sjögren's syndrome to facilitate the process in clinical routine. Patients with both CIDP and Sjögren's syndrome and CIDP without Sjögren's syndrome were compared concerning relevant differences in clinical, laboratory and electrophysiological findings. 154 patients who fulfilled the diagnostic EFNS/PNS criteria for CIDP were included in the analysis. 54 of these patients additionally fulfilled the ACR/EULAR classification criteria for Sjögren's syndrome. The frequency of female patients was higher in patients with CIDP and Sjögren's syndrome (52%) versus CIDP patients without Sjögren's syndrome (28%). Furthermore, the occurrence of cranial nerve impairment was significantly higher in patients with Sjögren's syndrome (39% versus 14%). There were no significant group differences in the evaluation of initial symptoms, severity of disability judged by INCAT disability scale score, presence or distribution of sensory deficits, limb weakness and the presence of ataxia, pain or dysautonomia, CSF laboratory or electrophysiological findings. In conclusion, our data indicate that cranial nerve impairment and female gender might represent red flags for an additional Sjögren's syndrome in patients with CIDP. The patterns of clinical disabilities and electrophysiological findings due to peripheral nerve damage are similar in both CIDP entities.
Sections du résumé
BACKGROUND
BACKGROUND
This study addresses the challenging characterisation and differentiation of CIDP versus CIDP in association with Sjögren's syndrome to facilitate the process in clinical routine.
METHODS
METHODS
Patients with both CIDP and Sjögren's syndrome and CIDP without Sjögren's syndrome were compared concerning relevant differences in clinical, laboratory and electrophysiological findings. 154 patients who fulfilled the diagnostic EFNS/PNS criteria for CIDP were included in the analysis. 54 of these patients additionally fulfilled the ACR/EULAR classification criteria for Sjögren's syndrome.
RESULTS
RESULTS
The frequency of female patients was higher in patients with CIDP and Sjögren's syndrome (52%) versus CIDP patients without Sjögren's syndrome (28%). Furthermore, the occurrence of cranial nerve impairment was significantly higher in patients with Sjögren's syndrome (39% versus 14%). There were no significant group differences in the evaluation of initial symptoms, severity of disability judged by INCAT disability scale score, presence or distribution of sensory deficits, limb weakness and the presence of ataxia, pain or dysautonomia, CSF laboratory or electrophysiological findings.
CONCLUSIONS
CONCLUSIONS
In conclusion, our data indicate that cranial nerve impairment and female gender might represent red flags for an additional Sjögren's syndrome in patients with CIDP. The patterns of clinical disabilities and electrophysiological findings due to peripheral nerve damage are similar in both CIDP entities.
Identifiants
pubmed: 33611611
doi: 10.1007/s00415-021-10459-z
pii: 10.1007/s00415-021-10459-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2908-2912Informations de copyright
© 2021. Springer-Verlag GmbH, DE part of Springer Nature.
Références
Sjögren H (1933) Zur kenntnis der keratoconjunctivitis sicca. Acta Ophthalmol 13:1–39
doi: 10.1111/j.1755-3768.1935.tb04186.x
Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109. https://doi.org/10.1136/ard.2009.110619
doi: 10.1136/ard.2009.110619
pubmed: 19561361
Ramos-Casals M, Brito-Zerón P, Seror R et al (2015) Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatol (Oxf) 54:2230–2238. https://doi.org/10.1093/rheumatology/kev200
doi: 10.1093/rheumatology/kev200
Jaskólska M, Chylińska M, Masiak A et al (2020) Neuro-Sjögren: uncommon or underestimated problem? Brain Behav. https://doi.org/10.1002/BRB3.1665
doi: 10.1002/BRB3.1665
pubmed: 32583978
pmcid: 7428478
Thiele T, Seeliger T, Witte T et al (2020) Severe polyneuropathy in primary Sjögren’s syndrome: Sjögren’s syndrome should be considered in patients with motor neuropathy. Z Rheumatol 79:707–709
doi: 10.1007/s00393-020-00821-3
Seeliger T, Prenzler NK, Gingele S et al (2019) Neuro-Sjögren: peripheral neuropathy with limb weakness in Sjögren’s Syndrome. Front Immunol 10:1600. https://doi.org/10.3389/fimmu.2019.01600
doi: 10.3389/fimmu.2019.01600
pubmed: 31354737
pmcid: 6637792
Perzyńska-Mazan J, Maślińska M, Gasik R (2020) Neurophysiological features of peripheral nervous system involvement and immunological profile of patients with primary Sjögren Syndrome. J Rheumatol. https://doi.org/10.3899/jrheum.181464 (jrheum.181464)
doi: 10.3899/jrheum.181464
pubmed: 32062606
Delalande S, de Seze J, Fauchais A-L et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Med (Baltim) 83:280–291
doi: 10.1097/01.md.0000141099.53742.16
Teixeira F, Moreira I, Silva AM et al (2013) Neurological involvement in primary Sjögren syndrome. Acta Reumatol Port 38:29–36
pubmed: 24131909
Van den Bergh PYK, Hadden RDM, Bouche P et al (2010) European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society: first revision. Eur J Neurol 17:356–363. https://doi.org/10.1111/j.1468-1331.2009.02930.x
doi: 10.1111/j.1468-1331.2009.02930.x
pubmed: 20456730
Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome. Ann Rheum Dis 76:9–16. https://doi.org/10.1136/annrheumdis-2016-210571
doi: 10.1136/annrheumdis-2016-210571
pubmed: 27789466
Hughes R, Bensa S, Willison H et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201
doi: 10.1002/ana.1088
Stålberg E, Falck B, Gilai A et al (1999) Standards for quantification of EMG and neurography. The international federation of clinical neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 52:213–220
pubmed: 10590989
Schwenkenbecher P, Chacko LP, Wurster U et al (2016) Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. BMC Neurol 16:136. https://doi.org/10.1186/s12883-016-0657-5
doi: 10.1186/s12883-016-0657-5
pubmed: 27515847
pmcid: 4981998
Seror R, Theander E, Brun JG et al (2015) Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866. https://doi.org/10.1136/annrheumdis-2013-204615
doi: 10.1136/annrheumdis-2013-204615
pubmed: 24442883
Seeliger T, Bönig L, Witte T et al (2020) Hearing dysfunction in patients with Neuro-Sjögren: a cross-sectional study. Ann Transl Med 8:1069–1069. https://doi.org/10.21037/atm-20-1856
doi: 10.21037/atm-20-1856
pubmed: 33145288
pmcid: 7575973
Mori K, Iijima M, Koike H et al (2005) The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 128:2518–2534. https://doi.org/10.1093/brain/awh605
doi: 10.1093/brain/awh605
pubmed: 16049042
Carvajal Alegria G, Guellec D, Mariette X et al (2016) Epidemiology of neurological manifestations in Sjögren’s syndrome: data from the French ASSESS Cohort. RMD open 2:e000179. https://doi.org/10.1136/rmdopen-2015-000179
doi: 10.1136/rmdopen-2015-000179
pubmed: 27110384
pmcid: 4838763
Phuljhele S, Pujari A, Obedulla H et al (2019) Atypical presentation of primary Sjögren’s syndrome as optic neuritis. Can J Ophthalmol 54:e30–e32
doi: 10.1016/j.jcjo.2018.04.013
Pars K, Pul R, Schwenkenbecher P et al (2017) Cerebrospinal fluid findings in neurological diseases associated with Sjögren’s syndrome. Eur Neurol 77:91–102. https://doi.org/10.1159/000454765
doi: 10.1159/000454765
pubmed: 27997917
Hughes RAC, Bouche P, Cornblath DR et al (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripher. Eur J Neurol 13:326–332. https://doi.org/10.1111/j.1468-1331.2006.01278.x
doi: 10.1111/j.1468-1331.2006.01278.x
pubmed: 16643309
Beeson PB (1994) Age and sex associations of 40 autoimmune diseases. Am J Med 96:457–462
doi: 10.1016/0002-9343(94)90173-2
Alamanos Y, Tsifetaki N, Voulgari PV et al (2006) Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology 45:187–191. https://doi.org/10.1093/rheumatology/kei107
doi: 10.1093/rheumatology/kei107
pubmed: 16332955
Izmirly PM, Buyon JP, Wan I et al (2018) The incidence and prevalence of adult primary Sjögren’s syndrome in New York county. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.23707
doi: 10.1002/acr.23707
Lunn MP, Manji H, Choudhary PP et al (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 66:677–680
doi: 10.1136/jnnp.66.5.677
Chio A, Cocito D, Bottacchi E et al (2007) Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 78:1349–1353. https://doi.org/10.1136/jnnp.2007.114868
doi: 10.1136/jnnp.2007.114868
pubmed: 17494979
pmcid: 2095630
Laughlin RS, Dyck PJ, Melton LJ et al (2009) Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73:39–45. https://doi.org/10.1212/WNL.0b013e3181aaea47
doi: 10.1212/WNL.0b013e3181aaea47
pubmed: 19564582
pmcid: 2707109
Sivadasan A, Muthusamy K, Patel B et al (2017) Clinical spectrum, therapeutic outcomes, and prognostic predictors in Sjogren’s syndrome-associated neuropathy. Ann Indian Acad Neurol 20:278–283. https://doi.org/10.4103/aian.AIAN_116_17
doi: 10.4103/aian.AIAN_116_17
pubmed: 28904462
pmcid: 5586125
Rajabally YA, Attarian S, Delmont E (2020) Evolving immunologic perspectives in chronic inflammatory demyelinating polyneuropathy. J Inflamm Res 13:543–549
doi: 10.2147/JIR.S224781